Press Releases

October 21, 2009

MacuSight® Receives Fast Track Designation from FDA for Perceiva™ in Treatment of Diabetic Macular Edema

September 30, 2009

MacuSight® Provides Clinical Development Update for Perceiva™

November 6, 2008

MacuSight Appoints Gerald Wroblewski Vice President of Operations

June 2, 2008

Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions

February 25, 2008

MacuSight™ Announces Positive Preliminary Results from Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration

February 20, 2008

MacuSight™ Expands Management Team with Appointment of Dr. Joel Naor as Chief Medical Officer

October 1, 2007

MacuSight™ Announces Positive Initial Results From Phase 1 Study Of Sirolimus In Diabetic Macular Edema

April 10, 2007

MacuSight™ To Present At IBC’s 4th International Conference On Ocular Anti-Angiogenesis

November 2, 2006

MacuSight™ Appoints Brian C. Cunningham to Board of Directors

October 31, 2006

MacuSight™ Initiates Wet Age-Related Macular Degeneration Study

September 26, 2006

MacuSight™ Initiates First Phase 1 Study of Novel Ophthalmic Drug Candidate

August 8, 2006

MacuSight™ Announces FDA Acceptance of IND for Novel Ophthalmic Drug Candidate

• Investors & Media
• Press Releases
• Financing Overview
• Contacts